Humacyte, Inc. (HUMA)

Market Cap	567.43M
Revenue (ttm)	n/a
Net Income (ttm)	-152.87M
Shares Out	128.67M
EPS (ttm)	-1.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,243,802
Open	4.500
Previous Close	4.480
Day's Range	4.300 - 4.600
52-Week Range	2.550 - 9.970
Beta	1.32
Analysts	Strong Buy
Price Target	13.43 (+204.54%)
Earnings Date	Nov 8, 2024

About HUMA

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 185
• Stock Exchange: NASDAQ
• Ticker Symbol: HUMA
• Website: https://www.humacyte.com

Analyst Forecast

According to 7 analysts, the average rating for HUMA stock is "Strong Buy." The 12-month stock price forecast is $13.43, which is an increase of 204.54% from the latest price.

Price Target

$13.43

(204.54% upside)

Analyst Consensus: Strong Buy